Weekly Research Analysts’ Ratings Changes for Ascendis Pharma A/S (ASND)

Ascendis Pharma A/S (NASDAQ: ASND) recently received a number of ratings updates from brokerages and research firms:

• 5/15/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Evercore Inc. They now have a $329.00 price target on the stock.
• 5/11/2026 – Ascendis Pharma A/S had its price target raised by Barclays PLC from $342.00 to $345.00. They now have an “overweight” rating on the stock.
• 5/9/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/8/2026 – Ascendis Pharma A/S had its price target lowered by Wells Fargo & Company from $330.00 to $326.00. They now have an “overweight” rating on the stock.
• 4/16/2026 – Ascendis Pharma A/S had its price target raised by Bank of America Corporation from $262.00 to $292.00. They now have a “buy” rating on the stock.
• 4/9/2026 – Ascendis Pharma A/S had its “outperform” rating reaffirmed by Wedbush. They now have a $273.00 price target on the stock.

Insiders Place Their Bets

In other Ascendis Pharma A/S news, insider Flemming Steen Jensen sold 19,460 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 40.00% of the stock is owned by company insiders.

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.